J. N. Wells

发表

Mechanism and function of cAMP- and cGMP-dependent protein kinases.

J. Corbin, P. Blackmore, S. Beebe, 1988, Advances in second messenger and phosphoprotein research.

Covalent modification of transmembrane span III of the A1 adenosine receptor with an antagonist photoaffinity probe.

J. Linden, J. N. Wells, A. P. Kennedy, 1996, Molecular pharmacology.

Cyclic nucleotide phosphodiesterase activities from pig coronary arteries. Lack of interconvertibility of major forms.

J. Hardman, J. N. Wells, T. Keravis, 1980, Biochimica et biophysica acta.

Structure Activity Relationships of Xanthines as Inhibitors of Cyclic Nucleotide Phosphodiesterases and as Antagonists of Adenosine Receptors

J. N. Wells, T. Katsushima, L. Nieves, 1990 .

Adenosine A2B receptors as therapeutic targets

I. Biaggioni, I. Feoktistov, J. N. Wells, 1998 .

Inhibition of human mast cell activation with the novel selective adenosine A(2B) receptor antagonist 3-isobutyl-8-pyrrolidinoxanthine (IPDX)(2).

I. Biaggioni, L. Belardinelli, E. Garland, 2001, Biochemical pharmacology.

Characteristics of a new binding protein distinct from the kinase for guanosine 3':5'-monophosphate in rat platelets.

P. Hamet, D. Franks, J. N. Wells, 1980, Biochimica et biophysica acta.

Relaxation of pig coronary arteries by new and potent cGMP analogs that selectively activate type I alpha, compared with type I beta, cGMP-dependent protein kinase.

J. Corbin, B. Jastorff, S. Francis, 1992, Molecular pharmacology.

Effects of isoproterenol on active force and Ca2+ X calmodulin-sensitive phosphodiesterase activity in porcine coronary artery.

J. N. Wells, J. Miller, 1987, Biochemical pharmacology.

Serine and alanine mutagenesis of the nine native cysteine residues of the human A(1) adenosine receptor.

D. Scholl, J. N. Wells, J N Wells, 2000, Biochemical pharmacology.

Effects of phosphodiesterase inhibitors on cyclic nucleotide levels and relaxation of pig coronary arteries.

J. N. Wells, G. L. Kramer, 1979, Molecular pharmacology.

Identification of the phosphodiesterase regulated by muscarinic cholinergic receptors of 1321N1 human astrocytoma cells.

T. K. Harden, J. N. Wells, M. Martin, 1986, Molecular pharmacology.

Inhibition of separated forms of cyclic nucleotide phosphodiesterase from pig coronary arteries by 1,3-disubstituted and 1,3,8-trisubstituted xanthines.

J. N. Wells, J. Garst, G. L. Kramer, 1981, Journal of medicinal chemistry.

Involvement of a plasma membrane phosphodiesterase in the negative control of cyclic AMP levels by vasopressin in rat hepatocytes.

C. Erneux, J. N. Wells, S. Keppens, 1988, Biochemical pharmacology.

Contraction of Isolated Porcine Coronary Arteries is Inhibited by High Concentrations of Propranolol

D. Robertson, R. Robertson, J. N. Wells, 1995, Angiology.

Rigid analogs of indomethacin.

W. J. Wheeler, J. N. Wells, D. R. Olson, 1974, Journal of medicinal chemistry.

Mechanism of the mannich reaction involving 2,4-dimethylphenol and morpholine

J. N. Wells, J. Burckhalter, William J. Mayer, 1964 .

Inhibition of cyclic nucleotide phosphodiesterases from pig coronary artery by benzo-separated analogues of 3-isobutyl-1-methylxanthine.

J. N. Wells, S. Schneller, E. Martinson, 1986, Journal of Medicinal Chemistry.

Aziridine derivatives as potential monoamine oxidase inhibitors.

J. N. Wells, A. Knevel, A. Shirodkar, 1966, Journal of medicinal chemistry.

Synthesis of azetidines.

J. N. Wells, O. R. Tarwater, 1971, Journal of pharmaceutical sciences.

The synthesis of 2-azetidinones.

J. N. Wells, R. E. Lee, 1969, The Journal of organic chemistry.

Alkylxanthines: inhibition of adenosine-elicited accumulation of cyclic AMP in brain slices and of brain phosphodiesterase activity.

J. Daly, J. N. Wells, C. Davis, 1979, Life sciences.

Biochemical events associated with activation of smooth muscle contraction.

J. Stull, K. Kamm, J. N. Wells, 1988, The Journal of biological chemistry.

Endogenous adenosine restrains renin release in conscious rats.

E. Jackson, J. N. Wells, C. Kuan, 1990, Circulation research.

1-Acyl-2,4,5-triphenyl-3-imidazolines

J. N. Wells, P. E. Manni, O. R. Tarwater, 1972 .

Evidence for essential histidine and cysteine residues in calcium/calmodulin-sensitive cyclic nucleotide phosphodiesterase.

C. Foster, J. N. Wells, E. Sybertz, 1991, Biochemistry.

Receptors Coupled to Pertussis Toxin-sensitive G-proteins Traffic to Opposite Surfaces in Madin-Darby Canine Kidney Cells

J. Keefer, C. Saunders, L. Limbird, 1996, The Journal of Biological Chemistry.

Cyclic nucleotide phosphodiesterase activities of pig coronary arteries.

J. N. Wells, C. Baird, Y. J. Hardman, 1975, Biochimica et biophysica acta.

Imidazole derivatives as inhibitors of cyclic nucleotide phosphodiesterases.

J. N. Wells, P. Heinstein, R. Buchman, 1974, Journal of Medicinal Chemistry.

Nucleoside 3',5'-monophosphate phosphodiesterases in sea urchin sperm.

D. Garbers, J. N. Wells, 1976, Biology of reproduction.

IMIDAZOLE DERIVATIVES AS INHIBITORS OF CYCLIC NUCLEOTIDE PHOSPHODIESTERASES

J. N. Wells, P. Heinstein, R. Buchman, 1975 .

Synthesis of 3'-aminopteroic acid.

J. N. Wells, M. Strahl, 1971, Journal of pharmaceutical sciences.

Phosphodiesterases from porcine coronary arteries: inhibition of separated forms by xanthines, papaverine, and cyclic nucleotides.

J. Hardman, J. N. Wells, C. Baird, 1975, Molecular pharmacology.

The effects of alkylated xanthines on cyclic AMP accumulation in dog thyroid slices exposed to carbamylcholine.

J. Dumont, F. Miot, C. Erneux, 1984, Molecular pharmacology.

Potentiation of the effects of sodium nitroprusside and of isoproterenol by selective phosphodiesterase inhibitors.

K. Lorenz, J. N. Wells, 1983, Molecular pharmacology.

Selective inhibition of cyclic nucleotide phosphodiesterases by analogues of 1-methyl-3-isobutylxanthine.

J. N. Wells, J. Garst, G. L. Kramer, 1977, Biochemistry.

Phosphodiesterase inhibitors as tools in cyclic nucleotide research: A precautionary comment

J. N. Wells, G. L. Kramer, 1981, Molecular and Cellular Endocrinology.

Antagonism by diphenylaminoethanol of GABA-induced inhibition of deiters neurones

J. N. Wells, S. Sangiah, J. Sinclair, 1975, Neuropharmacology.

Functional properties of covalent beta-endorphin peptide/calmodulin complexes. Chlorpromazine binding and phosphodiesterase activation.

N. Ling, D. Giedroc, J. V. Staros, 1985, Biochemistry.

Resistance of a separated form of canine ureteral phosphodiesterase activity to inhibition by xanthines and papaverine.

J. Hardman, J. N. Wells, R. M. Weiss, 1981, Biochemical pharmacology.

Xanthines and skeletal muscle: lack of relationship between phosphodiesterase inhibition and increased twitch tension in rat diaphragms.

J. N. Wells, G. L. Kramer, 1980, Molecular pharmacology.

Differences in the association of calmodulin with cyclic nucleotide phosphodiesterase in relaxed and contracted arterial strips.

J. Hardman, J. N. Wells, Y. Saitoh, 1985, Biochemistry.

Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase.

J. Corbin, S. Francis, J. N. Wells, 1988, Molecular pharmacology.

[46] Methylxanthine inhibitors of phosphodiesterases

Jerry R. Miller, J. N. Wells, 1988 .

Selective phosphodiesterase inhibition and alterations of cardiac function by alkylated xanthines.

R. Boerth, P. Mushlin, J. N. Wells, 1981, Molecular Pharmacology.

Inhibition of cyclic nucleotide phosphodiesterases in muscle

J. N. Wells, J. Miller, 1983 .

Structure-activity relationships of 8-cycloalkyl-1,3-dipropylxanthines as antagonists of adenosine receptors.

J. N. Wells, T. Katsushima, L. Nieves, 1990, Journal of medicinal chemistry.

Potent adenosine receptor antagonists that are selective for the A1 receptor subtype.

R. A. Johnson, J. N. Wells, E. Martinson, 1987, Molecular pharmacology.

A photoaffinity probe covalently modifies the catalytic site of the cGMP-binding cGMP-specific phosphodiesterase (PDE-5)

J. Corbin, I. Turko, S. Francis, 2007, Cell Biochemistry and Biophysics.

Methylxanthine inhibitors of phosphodiesterases.

J. N. Wells, J. Miller, 1988, Methods in enzymology.

A novel mechanism of soluble guanylate cyclase stimulation: time-dependent activation by bacterial lipopolysaccharide in rat fetal spleen cells.

R. Gerzer, J. N. Wells, S. Graber, 1988, Biochimica et biophysica acta.

The effects of chronic caffeine administration on peripheral adenosine receptors.

J. N. Wells, Y Zhang, J N Wells, 1990, The Journal of pharmacology and experimental therapeutics.

A carboxyl-terminally truncated mutant and nonglycosylated A2a adenosine receptors retain ligand binding.

J. N. Wells, C. True, C. E. Piersen, 1994, Molecular pharmacology.

Determination of amino acid residues that are accessible from the ligand binding crevice in the seventh transmembrane-spanning region of the human A(1) adenosine receptor.

E. Dawson, J. N. Wells, 2001, Molecular pharmacology.

Phorbol diesters alter the contractile responses of porcine coronary artery.

J. N. Wells, J. Miller, D. Hawkins, 1986, The Journal of pharmacology and experimental therapeutics.

Endogenous adenosine restrains renin release during sodium restriction.

E. Jackson, J. N. Wells, C. Kuan, 1989, The Journal of pharmacology and experimental therapeutics.

1-Isoamyl-3-isobutylxanthine: a remarkably potent agent for the potentiation of norepinephrine, histamine, and adenosine-elicited accumulations of cyclic AMP in brain slices.

J. Daly, J. N. Wells, F. Smellie, 1979, Life sciences.

Inhibition of separated forms of phosphodiesterases from pig coronary arteries by uracils and by 7-substituted derivatives of 1-methyl-3-isobutylxanthine.

J. N. Wells, J. Garst, G. L. Kramer, 1976, Journal of medicinal chemistry.

Xanthine accumulation by normal and SV40-transformed WI-38 fibroblasts.

R. Chamberlain, J. N. Wells, G. M. Nemecek, 1983, Biochemical Pharmacology.

INHIBITION OF SEPARATED FORMS OF PHOSPHODIESTERASES FROM PIG CORONARY ARTERIES BY URACILS AND BY 7-SUBSTITUTED DERIVATIVES OF 1-METHYL-3-ISOBUTYLXANTHINE

J. N. Wells, J. Garst, G. L. Kramer, 1976 .

Synthesis of aldoxime analogs of arecoline as reactivators of organophosphorus inhibited cholinesterase.

J. N. Wells, D. Haubrich, I. Boime, 1967, Journal of pharmaceutical sciences.

Fate of 2-phenethylamino-1-phenylethanol,2-14C in rats.

J. N. Wells, W. G. Andrus, 1969, Journal of pharmaceutical sciences.

Negative regulation of cyclic AMP levels by activation of cyclic nucleotide phosphodiesterases: the example of the dog thyroid.

J. Dumont, F. Miot, C. Erneux, 1984, Advances in cyclic nucleotide and protein phosphorylation research.